Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: massard c. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Clinical Trial.
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Rajpar S, Massard C, Laplanche A, Tournay E, Gross-Goupil M, Loriot Y, Di Palma M, Bossi A, Escudier B, Chauchereau A, Fizazi K. Rajpar S, et al. Among authors: massard c. Ann Oncol. 2010 Sep;21(9):1864-1869. doi: 10.1093/annonc/mdq037. Epub 2010 Feb 24. Ann Oncol. 2010. PMID: 20181574 Free article.
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
Massard C, Plantade A, Gross-Goupil M, Loriot Y, Besse B, Raynard B, Blot F, Antoun S, Nitenberg G, Escudier B, Fizazi K. Massard C, et al. Ann Oncol. 2010 Aug;21(8):1585-1588. doi: 10.1093/annonc/mdq021. Epub 2010 Feb 24. Ann Oncol. 2010. PMID: 20181575 Free article.
[Bladder cancer and new drugs].
Massard C, Albouy B, Gross-Goupil M, Ravaud A. Massard C, et al. Bull Cancer. 2010;97 Suppl Cancer de la vessie:43-50. doi: 10.1684/bdc.2010.1100. Bull Cancer. 2010. PMID: 20534389 French.
How to select targeted therapy in renal cell cancer.
Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. Escudier B, et al. Among authors: massard c. Ann Oncol. 2010 Oct;21 Suppl 7:vii59-62. doi: 10.1093/annonc/mdq371. Ann Oncol. 2010. PMID: 20943644 Free article. Review.
Novel and bone-targeted agents for CRPC.
Fizazi K, Albiges L, Massard C, Escudier B, Loriot Y. Fizazi K, et al. Among authors: massard c. Ann Oncol. 2012 Sep;23 Suppl 10:x264-7. doi: 10.1093/annonc/mds353. Ann Oncol. 2012. PMID: 22987974 Free article.
464 results